Home GPCR & G Protein Adrenergic Receptor agonist Terbutaline Sulfate

research use only

Terbutaline Sulfate Adrenergic Receptor agonist

Cat.No.S4127

Terbutaline Sulfate(Terbutaline hemisulfate) is a selective β2-adrenergic receptor agonist with IC50 of 53 nM.
Terbutaline Sulfate Adrenergic Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 548.65

Jump to

Quality Control

Batch: S412701 Water]100 mg/mL]false]DMSO]Insoluble]false]Ethanol]Insoluble]false Purity: 99.94%
99.94

Solubility

In vitro
Batch:

Water : 100 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 548.65 Formula

C24H38N2O6.H2SO4

 Storage (From the date of receipt)
CAS No. 23031-32-5 Download SDF Storage of Stock Solutions

Synonyms Terbutaline hemisulfate SMILES CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
β2-adrenergic receptor
53 nM
In vitro

Terbutaline is a relatively selective β2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on β2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline inhibits antigen-induced histamine release from passively sensitized human lung tissue, which contributes to the clinical effectiveness of the drug during treatment of allergic asthma. Terbutaline also shows competitive reversible inhibition for all BChE variants. The dissociation constants for UU, FF and AA homozygotes are 0.18, 0.31 and 3.3 mM, respectively.

In vivo

Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (β2 receptors) than on the beta-receptors of the heart (β1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-15)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06980727 NOT_YET_RECRUITING
Renal Colic
University of Monastir
 2026-08-08 PHASE3
NCT05193968 RECRUITING
Hot Flashes; Menopause; Vasomotor System; Labile
Mayo Clinic
 2022-02-24
NCT04973345 WITHDRAWN
Asthma
Kanecia Obie Zimmerman
 2023-07-07 PHASE2; PHASE3
NCT06626620 COMPLETED
Acute Exacerbation of Asthma
Muhammad Aamir Latif
 2024-01-01 PHASE3
NCT06199154 Not yet recruiting
Morbid Obesity|Pregnancy
University of Maryland Baltimore
 2024-05 Early Phase 1
NCT05494307 UNKNOWN
Immune Thrombocytopenia
Peking University People's Hospital
 2022-09-01 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map